Linaclotide
- TRADE NAME: Linzess (Forest)
- INDICATIONS: Irritable bowel syndrome with constipation and chronic idiopathic constipation
- CLASS: Amino acid, Guanylate cyclase-C agonist
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Contra-indicated in patients with known or suspected mechanical gastrointestinal obstruction.
PEDIATRIC RISK
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 01/12/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric